This review focuses on the clinical and pathophysiological connections between NAFLD, insulin resistance, and type 2 diabetes. Current available GLP-1 RA liraglutide and semaglutide might improve obesity and T2DM that impact each stage of NAFLD. Understanding the NAFLD spectrum correctly, which encompasses a range from obesity to metabolic syndrome and diabetes, could aid in the early detection and implementation of tailored therapeutic approaches. The gene discussed is GCG; the disease is metabolic syndrome.